Human BRCA1 has a genetically demonstrated role in DNA repair, and has been proposed to act as a transcriptional activator in a limited number of specialized settings. To gain insight into biologically conserved functional motifs, we isolated an ortholog of BRCA1 from cattle (Bos taurus). The predicted protein product shows 72.5% sequence identity with the human protein and conservation of amino acids involved in BRCA1 structure and function. Although the bovine C-terminus is truncated by seven amino acids as compared to human, bovine BRCA1 protein exhibited a similar cell cycleregulated nuclear expression pattern. Expression was characteristically low and diffuse in the nucleus of G1/G0 cells, followed by increasing BRCA1-positive nuclear speckles in late S phase and G2/M phase cells. Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents. Consistent with evidence from studies of human BRCA1, bovine BRCA1 was shown to interact with RNA polymerase II in vivo, an activity that was mapped to the C-terminal domain (CTD) (bBRCA ). Interestingly, when tested in the GAL4 transcriptional activation assay, fulllength bovine and human BRCA1 lacked any ability to act as transcriptional activators and the CTD of bovine BRCA1 had five-fold lower activity when compared to the more acidic human C-terminus. These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress. In addition, bovine BRCA1 binds the RNA polymerase II holoenzyme, but this interaction lacks significant ability to correctly orient or recruit RNA polymerase II for transcription in the classic GAL4 transcriptional activation system.
Introduction
Mutations in the gene encoding BRCA1 are associated with an increased risk of inherited breast and ovarian cancers (Antoniou et al., 2000) . While the function of BRCA1 is still controversial, both genetic and biochemical data support roles in DNA double-strand break repair, homologous recombination, and chromatin remodeling (reviewed in Scully and Livingston, 2000) . In addition, BRCA1 protein possesses structural and functional features of an E3-ubiquitin ligase (Ruffner et al., 2001; Chen et al., 2002) . Within mammals, BRCA1 genes show high degrees of divergence (Madsen et al., 2001) . However, it is likely that important structural and functional elements have been conserved since human BRCA1 (hBRCA1) can genetically complement loss-of-function alleles in mice, in which BRCA1 has less than 60% amino-acid identity (Lane et al., 2000; Chandler et al., 2001) .
One line of investigation has indicated that at least a subset of BRCA1 associates with components of the transcriptional machinery, and certain results suggest a specific capacity to act as a transcriptional activator (reviewed in Monteiro, 2000) . Transcriptional activators are sequence-specific DNA binding proteins that, with the help of coactivators, recruit the basal transcriptional machinery to the promoter (Featherstone, 2002) . Initial studies in this area showed that fusion of the CTD of BRCA1 to heterologous DNA binding domains (DBD) from GAL4 or LexA resulted in modest activation of a reporter gene (Chapman and Verma, 1996; Monteiro et al., 1996) . When full-length human BRCA1 cDNA is artificially over-expressed in mammalian cells, there is increased transcription of several stress-response genes, including p21 (Somasundaram et al., 1997) , p27 (Williamson et al., 2002) and GADD45 (Harkin et al., 1999) , and decreased transcription of other genes, including c-Myc (Li et al., 2002) and certain estrogen receptor-regulated genes (Fan et al., 1999) . Furthermore, human BRCA1 has been shown to interact with RNA polymerase II (Scully et al., 1997a) , CBP/p300 (Pao et al., 2000) , HDAC 1 and 2 (Yarden and Brody, 1999) and transcription factors such as CtIP (Yu et al., 1998) , STAT1 (Ouchi et al., 2000) , OCT-1 and NF-YA (Fan et al., 2002) . Nonetheless, to date there is no compelling evidence that full-length BRCA1 is capable of specific DNA binding to promoter or enhancer regions of these genes, or direct evidence for transactivation in vivo.
BRCT domains represent a protein fold found in a number of DNA repair and cell cycle regulatory proteins (Bork et al., 1997) . The C-terminus of BRCA1 is composed of two BRCT domains and a short sequence of additional amino acids (eight in human and 15 in mouse) that constitute a region we refer to as the 'C-terminal tail'. A high degree of significance has been attributed to the C-terminal tail because several disease-associated BRCA1 alleles truncate these amino acids in human BRCA1 kindreds. In particular, the 1853term mutation (Friedman et al., 1994) results in the deletion of 11 amino acids from human BRCA1 and diminishes or eliminates activity in a number of assay systems (Chapman and Verma, 1996; Monteiro et al., 1996) . The crystal structure of the tandem BRCT domains in human BRCA1 (Williams et al., 2001) reveals that two hydrophobic residues at the C-terminus of the second BRCT domain (Leu 1854 and Ile 1855 ) are critical to folding, but that amino acids within the tail region are less ordered. Thus, the 1853term mutation may result in decreased structural integrity of the BRCT motif, an interpretation that would place reduced importance on the aminoacids distal to Ile 1855 .
Because of the high degree of sequence divergence between mouse and human C-terminal tails, we analysed mammalian ESTs to identify conserved features of the BRCA1 C-terminus. This search identified likely ESTs from cow (Bos taurus) and pig (Sus scrofa). The bovine BRCA1 (bBRCA1) EST (accession number AJ403968) provided evidence for an unusually short C-terminal tail. Alignment of human and bovine sequences showed that the bovine protein terminated just after the conserved hydrophobic pair (Leu 1847 Val 1848 ) corresponding to human Leu 1854 Ile 1855 , while retaining high overall identity to human BRCA1 in amino acids upstream of this position. The bovine sequence therefore confirms that the C-terminal tail is not required for native function of the BRCA1 protein. We reasoned that further analysis of the bovine BRCA1 would provide additional insights into important features of human BRCA1.
The present study describes the first analysis of the BRCA1 ortholog from Bos taurus. We present the deduced sequence and provide evidence for its genomic localization on chromosome 19. To establish that the bovine allele was functional, we generated an antibody to the predicted sequence and identified bovine BRCA1 as a nuclear phosphoprotein with potential splice variants in bovine cells. We created a series of fusion proteins linking the DBD of GAL4 with various segments of the human and bovine sequence. In order to address critical questions suggested by studies of human and mouse BRCA1, bovine proteins were tested for expression, for interaction with the RNA polymerase II holoenzyme, and for their ability to stimulate transcription from GAL4-dependent promoters in mammalian cells. When we used amino acids that have previously been described as representing a transcriptional activation domain (AD) in the human Cterminus, bovine BRCA1 was shown to have minimal activity in the GAL4 assays. Full-length human or bovine BRCA1 fusions were also negative in these assays, suggesting that (i) additional sequences did not improve performance, and (ii) full-length BRCA1 proteins do not act as effective transcriptional activators when tethered to a promoter. Since human BRCA1 had previously been shown to interact with RNA polymerase II (Scully et al., 1997a) , we tested whether differential interaction with RNA polymerase II could explain the difference in apparent transcriptional activation activity. Interestingly, full-length bovine BRCA1 interacted with RNA polymerase in immunoprecipitation experiments, and the bovine C-terminus demonstrated greater affinity for RNA polymerase than the human C-terminus. These data provide evidence for an inverse relation between RNA polymerase II affinity (bovine4human) and response in the GAL4 activation assay (human4bovine).
Results

Cloning of bovine BRCA1
The deduced open reading frame of bovine BRCA1 spans 5550 nucleotides (accession number AY077732). Translation of this sequence predicts a protein of 1849 amino acids (Figure 1a ) with an estimated mass of 206 kDa. In addition, several potential splice forms (accession numbers AF479648 and AF479649) were identified from spleen, a tissue shown in other species to express high levels of BRCA1 mRNA (Lane et al., 2000) . From the analysis of multiple PCR products, major alternative splice forms in spleen include one variant (D11) lacking all sequences homologous to human and mouse exon 11, and a second form (D11b) in which a cryptic splice site is used within this exon (Figure 1b) . In cattle, the D11 splice variant is predicted to be 712 amino acids in length (encoding an 80 kDa protein) and lacks exon 11-related sequences completely, which would be similar in structure to the major splice variant reported for mouse BRCA1 (Mixon et al., 2000) . Bovine D11b contains the first 40 amino acids of the putative bovine exon 11 but lacks the remaining 1097 amino acids. The D11b splice variant is predicted to encode a protein of 85 kDa, and is more similar to the major splice form observed in human tissues (Bachelier et al., 2000) . These data confirm that the bovine BRCA1 locus contains a large exon that is variably spliced, and predict that bovine BRCA1 can be expressed either as a full-length protein, or as splice variants lacking most or all of exon 11.
Analysis of features of bovine BRCA1 protein structure
The presence of an N-terminal RING finger and two BRCT domains were predicted through computational analysis of the deduced amino-acid sequence. These structural motifs have been identified in all known BRCA1 sequences, including the human, mouse, rat, dog, chicken, Xenopus and Arabidopsis proteins (Miki et al., 1994; Lane et al., 1995; Szabo et al., 1996; Bennett et al., 1999; Joukov et al., 2001; Orelli et al., 2001) . Two putative nuclear localization signals, homologous to the human and mouse sequences, were detected within exon 11. Paircoil, a software program to identify coiled-coil motifs (Berger et al., 1995) , indicated a high probability of a coiled-coil motif from amino acids 1386-1419. This coiled-coil domain is evident in human and dog BRCA1 protein sequences, but is not identifiable in mouse BRCA1. A putative leucine zipper that is identifiable in Figure 1 Characterization of bovine BRCA1. (a) The predicted 1849 amino-acid translation product from the bovine BRCA1 cDNA (accession number AY077732). The RING finger is shown with a thick underline. The amino-terminal boundary of exon 11a was established within codon 227 and is marked with an 'a'. The amino-terminal boundary of exon 11b was established in codon 264 and is marked with a 'b'. The carboxy-terminal boundary of exon 11 is depicted with a triangle at codon 1361. Two conserved nuclear localization signals were identified in exon 11 and are marked with double lines. A predicted coiled-coil motif is indicated by the dashed line. The * denotes the beginning of the CTD domain used for binding and transcriptional activation assays. Arrows highlight the locations of the BRCT domains. (b) Model of three identified bovine BRCA1 splice forms. Exon 11 is spliced out in its entirety in the D11 form (accession number AF479648), whereas 37 amino acids of exon 11 are present in the D11b form (accession number AF479649). The bar identified as CTD illustrates the CTD. (c) Using a radiation hybrid panel, bovine BRCA1 was mapped as a single copy gene to chromosome 19, distal to CNP (LOD 18.8) and proximal to PYY (LOD 14.9) . In this analysis, LOD scores above 12 are considered significant (arrow) the human sequence (amino acids 1209-1230) is absent in bovine, canine and murine sequences. The bovine and murine proteins have three of the four leucines that are present in the putative human leucine zipper. However, computer-modeling algorithms do not indicate that a stable zipper is formed in bovine, canine and murine BRCA1.
Localization of bovine BRCA1 on BTA19
The BRCA1 locus was mapped to chromosome 19 (BTA19) using a 31-clone bovine-hamster somatic cell hybrid panel (98SCP31) (described in Adkison et al., 1988; Barendse et al., 1991) . This result was confirmed and extended by analysis of a 5000 Rad radiation hybrid panel (RHBov5RAD) (Band et al., 2000) . As shown in Figure 1c , bovine BRCA1 mapped next to CNP (2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase; LOD 18.8, y ¼ 0.09). Analysis of neighboring loci was consistent with a map location distal to CNP and proximal to PYY (peptide YY; LOD 14.9, y ¼ 0.16). Specifically, CNP mapped 8.8 cR centromeric, and PYY mapped 15.2 cR telomeric, to the position of BRCA1. This map location places BRCA1 within a region of conserved gene order (synteny) with human chromosome 17q21 (Miki et al., 1994) and mouse chromosome 11 (Lane et al., 1995) . No chromosomal abnormalities have been mapped to this region of BTA19, although there is evidence that elements within this region have undergone distinct duplication events in human and bovine (Hort et al., 1995; Brown et al., 1996) but not in mouse chromosomes .
Sequence conservation of bovine BRCA1
Comparison of BRCA1 orthologs from cow, human, mouse, rat, chicken and dog revealed varying degrees of conservation ( Figure 2a) . The bovine and human BRCA1 genes are more similar at the protein level (72.5%) than at the nucleotide level (55.7%). Of the known mammalian BRCA1 orthologs, the predicted bovine BRCA1 protein is most closely related to human (72.5%) and to canine (72.9%) sequences. Divergence of murine and bovine BRCA1 (54.1% identity) is roughly equivalent to the divergence of murine from human and dog sequences (57.0 and 54.3%, respectively) ( Figure 2b ). All mammalian orthologs share numerous stretches of near-perfect amino acid identity. These include the N-terminal ring finger motif and shorter sequences of unknown function interspersed throughout the protein.
The predicted bovine BRCA1 protein is 14 amino acids shorter than the human protein. This is due to two gaps one amino acid in length and an additional two and three amino-acid gaps. In addition, bovine BRCA1 lacks seven amino acids distal to a conserved proline that marks the C-terminus of the bovine protein. As shown in Figure 2c , the C-terminal proline (Pro 1849 ) of bovine BRCA1 defines the end of a highly conserved series of amino acids. The proline falls at the end of the second BRCT motif and directly follows twin aliphatic residues (L 1847 V 1848 ) which are predicted to anchor the C-terminus of the second BRCT motif (Williams et al., 2001) . The context of bovine Pro 1849 (YLIP 1849 ) is identical to that of Pro 1857 in the human sequence (YLVP 1857 ). The absence of an additional sequence in bovine BRCA1 and the poor conservation of more distal amino acids in other species suggest that amino acids distal to the twin aliphatic residues are hypervariable and largely dispensable for protein function. We suggest that these amino acids be referred to as the Cterminal tail to distinguish them from the structural BRCT motifs. 
Comparison of disease mutations
Disease-associated nonsense and missense mutations in the human BRCA1 sequence have been reported and cataloged in the Breast Cancer Information Core (http://www.nhgri.nih.gov/Intramural_research/ Lab_transfer/Bic/). More than 90% of the different germ line BRCA1 alterations identified (4600) truncate the coding sequence (Perrin-Vidoz et al., 2002) , and the majority of the other mutations affect expression levels to various extents. Only a handful of amino-acid substitution mutations (missense) are known which result in tumor promotion. Most of the diseaseassociated missense mutations result in elimination of cysteine residues within the N-terminal RING finger. Five other disease-associated mutations occur in other parts of the protein (see Table 1 ). Three of these (S1040, R1347 and M1775) are conserved in the bovine sequence, whereas two (R1347 and M1775) are conserved in the dog sequence and only one (M1775) is conserved in the mouse sequence. The C1372Y is listed as a disease allele, but may be a misclassified polymorphism since it aligns with Y residues in both the dog and mouse sequences and with H 1367 in bovine BRCA1.
Bovine BRCA1 is phosphorylated and relocates to nuclear foci after DNA damage and during the S phase of the cell cycle
To study BRCA1 protein, we generated antibodies to the bovine BRCA1-CTD (amino acids 1364-1849). These antibodies were extensively characterized through immunoblots and immunoprecipitation of native and transfected BRCA1 proteins in a variety of mammalian cell types. In immunoblots, the antibodies specifically reacted with bovine, canine and human BRCA1-CTDs, and to a lesser extent with the murine sequence, when these epitopes were introduced into human 293T cells ( Figure 3a ). In addition, the antibodies recognized fulllength BRCA1 immunoprecipitated from bovine testes (filled arrowhead) and human BRCA1 immunoprecipitated from HBL-100 cells (Figure 3b ). An additional protein band of approximately 80-100 kDa lower molecular weight (small arrow) was seen in bovine testes and bovine aortic endothelial cells (BAECs) (Figure 3b and c), which may represent translation of Miki et al. (1994) .
b Lane et al. (1995) .
c Szabo et al. (1996) Figure 3 Anti-bovine BRCA1 antisera recognize epitopes in bovine, human, dog and mouse BRCA1 proteins. (a) Anti-bovine BRCA1 antisera were characterized on immunoblots of BRCA1 CTDs from cow, dog, human and mouse. All proteins were generated as fusions to the GAL4 DBD. Plasmids were transfected into 293T cells and whole cell extracts were analysed by SDS-PAGE and immunoblotting with mouse anti-bovine BRCA1 sera. A parallel blot was probed with an anti-GAL4 antibody. The marker indicates the size of the CTDs. (b) Immunoprecipitation of BRCA1. Total cell lysate from bovine testes or nuclear extracts from human HBL100 cells were immunoprecipitated with antibovine BRCA1 antisera and the membrane was probed with a second antisera to bovine BRCA1. The predicted molecular weight of bovine BRCA1 is 206 kDa (filled triangle), and the predicted molecular weight of human BRCA1 is 208 kDa. A second band of slightly lower molecular weight (small arrow) was consistently identified in testis extracts and BAECs, and may represent an alternative splice form in this tissue. (c) BAECs were treated with or without 1 mm adriamycin for 4 h and then the total cell lysate was immunoprecipitated with anti-bovine BRCA1 antisera. The immunoprecipitated material was treated for 1 h with CIP, as indicated. The membrane was probed with antisera to bovine BRCA1. Lower panel, 2% of each cellular extract was analysed in a parallel experiment and probed with antisera to b-catenin to demonstrate equivalent loading. Filled triangles ¼ full-length bovine BRCA1. Open triangles ¼ phosphorylated full-length BRCA1. Small arrows ¼ presumed splice variant of bovine BRCA1 a splice variant. These antibodies did not identify any other proteins in immunoblots of a variety of human, mouse or bovine cells (data not shown). In order to determine whether bovine BRCA1 protein was phosphorylated in cycling cells and whether the phosphorylated state was modulated in response to DNA-damaging agents, normal, cycling cells were shown to contain both a phosphorylated (open arrowhead) and a hypo-or nonphosphorylated (filled arrowhead) BRCA1 (Figure 3c, lane 1) . Upon treatment of the immunoprecipitation product (pellet) with calf intestinal phosphatase (CIP) (Figure 3c , lane 2), the slowermigrating phosphorylated BRCA1 band was converted to a dephosphorylated form. Bovine BRCA1 was hyperphosphorylated after DNA damage as evidenced by a hypershifted species that appeared following treatment with the topoisomerase inhibitor adriamycin (doxorubicin) (Figure 3c , lane 3). The hyperphosphorylated band returned to the dephosphorylated size when the immunoprecipitated proteins were treated with CIP ( Figure 3c , lane 4).
Primary cultures of BAECs were also used to determine the subcellular localization of bovine BRCA1 protein. In asynchronous cells, two distinct staining patterns could be detected with antibodies generated against the bBRCA1-CTD. The first pattern was observed in G1/G0 cells (as determined by cytometric analysis). These cells displayed an overall low level of nuclear BRCA1 immunofluorescence with one, or a few, nuclear speckle(s) (Figure 4a ). In contrast, cells in late S or G2 showed elevated nuclear fluorescence localized mainly in a large number of distinct nuclear speckles (Figure 4b ). Both populations also demonstrated diffuse nuclear staining that may represent a significant proportion of the total BRCA1. Cells treated with DNA-damaging agents aphidicolin (Figure 4c ), hydroxyurea (HU) (Figure 4d ), or the topoisomerase inhibitors adriamycin and camptothecin (data not shown) exhibited increased fluorescence and a greater number of nuclear speckles per cell. A laser scanning cytometer was used to measure the mean intensity of BRCA1 immunofluorescence in each phase of the cell cycle (Figure 4e ). In addition, we compared the amount of BRCA1 in cells treated with serum-free media to that of cells treated with the S-phase inhibitors (Figure 4f ). An increase in nuclear staining intensity was seen as cells progressed from early S to late S and through G2, and in cells treated with DNA-damaging agents. Treatment of cells with serum-free media modulated BRCA1 immunofluorescence levels toward a state which closely mimicked that of G1/G0 cells, whereas S-phase arresting agents caused BRCA1 expression to increase to a state more similar to that of cells in late S (Figure 4e and f, data not shown).
BRCA1 interaction with RNA polymerase II
To demonstrate that bovine BRCA1 and its CTD encode stable, functional proteins, we tested for their abilities to interact with RNA polymerase II, as previously described for the human BRCA1 CTD (Scully et al., 1997a) . GST fusion proteins were incubated with cell extract from human HBL100 cells and bovine MDBK cells. Bound complexes were treated with phosphatase and eluted proteins were subjected to Figure 4 Bovine BRCA1 localizes to discrete nuclear dots in S and G2 phases of the cell cycle and in response to DNA-damaging agents. BAECs were used to determine the subcellular localization of bovine BRCA1. In asynchronous cells, two distinct staining patterns could be detected. Panel A shows fluorescence micrographs of 4 cells with 2N DNA (G0 or G1 cells), as determined by cytometric analysis of propidium iodide stained cells. These cells show low levels of BRCA1 staining throughout the entire nucleus. In contrast, cells that were in late S or early G2 phase of the cell cycle showed higher levels of nuclear fluorescence and strong localization to distinct nuclear speckles. (b) Cells that were treated with the S-phase inhibitors aphidicolin (aph) (c) and HU (d) exhibited high levels of fluorescence and nuclear foci. Staining of cells with secondary antibodies alone revealed no staining at the exposure settings used for these micrographs. Cytometric analysis of immunostained cells was used to show that BRCA1 levels increase in late S and G2/M cells. A laser scanning cytometer (LSC) was used to quantify the amount of cytosolic and nuclear immunofluorescence during each phase of the cell cycle (e) and after treatment with serum-free (SF) media (f), HU and aphidicolin. Arrows identify representative nuclear speckles. immunoblot analysis with antisera recognizing the 220 kDa catalytic subunit of RNA polymerase II. RNA polymerase II from human ( Figure 5a ) and bovine ( Figure 5b ) cells bound more avidly to the bovine CTD than they did to equimolar quantities of the human CTD. The panel marked a-GST (anti-GST) shows the amount of bovine and human CTD that were present in each experiment.
To demonstrate that native bovine BRCA1 interacted with RNA polymerase II, bovine MDBK cells were lysed and BRCA1 was immunoprecipitated. Cellular proteins that coprecipitated with bovine BRCA1 were treated with phosphatase and analysed by immunoblotting as described above. Again, RNA polymerase II coprecipitated with bovine BRCA1 (Figure 5c ). Immunoblots of the starting lysates showed equivalent levels of b-catenin, which demonstrated equivalent levels of protein in the starting extracts. These results confirm that the CTD of bovine BRCA1 forms a stable structure and support the hypothesis that at least a portion of BRCA1 interacts with the transcriptional machinery in mammalian cells.
Analysis of transcriptional activation activity of the CTD domains and full-length BRCA1 proteins
As shown above, bovine and human BRCA1 proteins interacted with the RNA polymerase II holoenzyme, as evidenced by the presence of the p220 subunit of RNA polymerase II in immunoprecipitation and binding assays. The interaction was maintained in segments of the BRCA1 proteins encoding their respective CTDs. The CTD of human BRCA1 (amino acids 1380-1863) had been implicated previously as a transcriptional activator in classical GAL4 fusion assays (Chapman and Verma, 1996; Monteiro et al., 1996; Chai et al., 1999) . With this model in mind, we tested whether bovine BRCA1 would also function as a direct transcriptional activator. We created GAL4 DBD fusions with homologous regions of human and bovine BRCA1 proteins. These fusions included amino acids 1380-1863 of human BRCA1 and the homologous region (1364-1849) of the bovine sequence since these sequences have been shown to be the most highly active in the human protein (Hu et al., 2000) . Plasmids containing the GAL4 DBD alone, or GAL4 DBD fused to BRCA1 sequences, were tested for their ability to activate transcription of a luciferase reporter plasmid with five direct repeats of the GAL4 upstream activation sequences (UAS) and an adenovirus E1B minimal promoter. While the human BRCA1-CTD activated transcription (21-29-fold over control), the comparable bovine domain showed significantly reduced activity (4-5-fold over control) in multiple experiments (Figure 6a ). When full-length bovine BRCA1 was fused to the GAL4 DBD, transactivation activity was reduced to below control levels. This result was also obtained when full-length human BRCA1 was fused with the GAL4 DBD, making it unlikely that the reduced activity of the bovine CTD resulted from the absence of critical regions of the protein. These assays were repeated in several human cell lines (including MCF-7 and T47D cells) and BAECs with similar results. Cell lysates from identical transfections were subjected to immunoblotting with an antibody to the GAL4 DBD to demonstrate comparable expression levels of the full-length and CTD fusion proteins (Figure 6b and c) . (The difference in electrophoretic mobility between bovine CTD and human CTD fusions is greater than the difference in predicted molecular mass (54 and 55 kDa) and results from the more acidic character of the human CTD sequence (À15 and À29) respectively. The effect of charge on the electrophoretic mobility of proteins also accounts for Figure 5 The C-terminus of bovine BRCA1 interacts with the 220 kDa catalytic subunit of RNA Polymerase II. Extracts from the human epithelial cell line HBLl00 (a) or the bovine cell line MDBK (b) were incubated with purified CTD from human or bovine BRCA1, generated as GST fusions. The products from GST pulldown assays were analysed by SDS-PAGE and immunoblotting with antisera to the 220 kDa RNA Polymerase II catalytic subunit. RNA Polymerase II (PolII) immunoprecipitation (IP) was run as a positive control. The lower panel of part B shows the same blot probed with an antibody to GST to show equivalent loading. (c) The upper panel shows that p220 RNA polymerase II coprecipitates with endogenous BRCA1 in cellular extracts. Antibodies against an irrelevant antigen (FLAG) or bovine BRCA1 were used in immunoprecipitation reactions with bovine MDBK cell lysates. Immunoprecipitated proteins were then run on an SDS-PAGE gel and blots of these gels were probed with an antibody to p220 RNA polymerase II (PolII). In the lower panel, antibodies to b-catenin were used to probe immunoblots representing 10% of the input protein to demonstrate equivalence of loading Structural analysis of bovine BRCA1 SA Krum et al the different apparent sizes for dog and mouse CTDs used in Figure 3 .) These results show that a portion of cellular BRCA1 interacts with the transcription complex in diverse mammalian species. However, the ability of the CTD to act as a transcriptional activator is contextdependent, and potentially charge-dependent, and may not be a highly conserved feature in mammalian BRCA1 homologs.
Discussion
We have identified a uniquely shortened bovine ortholog of the BRCA1 tumor suppressor gene. In other respects, bovine BRCA1 is 72.5% identical to the human BRCA1 protein, and contains numerous regions of near-identity with other mammalian BRCA1 proteins. Comparison of the deduced sequence placed bovine BRCA1 intermediate in homology between the well-characterized human and mouse proteins. The gene mapped to BTA19 within a region previously shown to have similar gene order as the BRCA1 locus in human (chromosome 17) and mouse (chromosome 11) (Lane et al., 1995; Yang and Womack, 1998) . During isolation of bovine cDNA sequences, several splice forms were identified. Sequences homologous to human and mouse D11 splice forms were observed. The major splice variant observed in human tissues, referred to as D11b, arises from a cryptic splice site downstream of the exon 11 border (Bachelier et al., 2000) . In contrast, the principal splice form in mice has been reported to lack exon 11 entirely (Xu et al., 1999) . Interestingly, both variants, D11 and D11b, were isolated from bovine spleen cDNA. In addition, an in-frame splice variant missing exon 3 was identified from testes (data not shown). It is unclear whether this form would be functional, as it eliminates part of the RING finger; however, all forms identified contain the complete CTD shown here to interact with RNA polymerase II.
Most of the known structural motifs identified in human BRCA1 are conserved in the bovine sequence. The N-terminal RING domain, the nuclear localization signals, a hypothetical coiled-coil motif, and the paired C-terminal BRCT domains were all found in the deduced sequences of human and bovine BRCA1. A leucine zipper identified by some sequence analysis programs in human BRCA1 is less obvious in the bovine and murine sequences (only three of four critical leucine residues are present in the bovine and murine sequences). While the overall identity with the human protein was 72.5%, the N-terminal RING finger and numerous patches of shorter length showed nearidentity between human and bovine BRCA1.
In order to demonstrate that the bovine BRCA1 protein has functional characteristics compatible with those identified in the human ortholog, we set out to identify the protein in bovine cells. Antisera against the protein demonstrated that bovine BRCA1 was a nuclear phosphoprotein. Similar to human BRCA1 (Scully et al., 1997c) , bovine BRCA1 was recruited to distinct subnuclear speckles in late S phase and in cells Over 850 distinct mutations, polymorphisms and variants of human BRCA1 have been identified throughout the human BRCA1 gene (Breast Cancer Information Core: http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/). Most disease alleles represent truncations or expression defects, and a much smaller number result from amino-acid substitutions (missense mutations). Since many of the proposed missense alleles are extremely rare, it has been difficult to assess with certainty whether they constitute bona fide disease alleles as opposed to polymorphisms in the human population. Analysis of evolutionarily conserved amino acids may provide a significant source of information in this analysis. To test this possibility, we examined the conservation of 11 amino acids that have been implicated, through human missense mutations, to play a role in predisposition to breast and ovarian cancer. Interestingly, bovine BRCA1 retains the identical amino acid as in the wild-type human sequence for nine of these amino acids, and one additional amino acid (human V1378, bovine L1373) represents a conservative substitution. From this analysis, the bovine BRCA1 sequence is a better predictor of disease alleles (versus polymorphisms) than either the murine or the canine sequences.
BRCA1 is hyperphosphorylated in S phase of the cell cycle (Scully et al., 1997c) and in response to DNA damage (Scully et al., 1997b) . Six serine/threonine kinases have been shown to phosphorylate BRCA1. These include ATM, ATR, Chk2, CDK2, AKT and casein kinase II. ATM, ATR and Chk2 phosphorylate BRCA1 on serines in response to different forms of DNA damage. ATM and Chk2 phosphorylate BRCA1 after g irradiation (IR), and ATR phosphorylates BRCA1 after IR, ultraviolet irradiation (UV) or treatment with HU. Human BRCA1 is also phosphorylated in response to growth stimuli. The cyclindependent kinase CDK2 phosphorylates serine 1497 during the G1/S phase of the cell cycle and AKT phosphorylates BRCA1 on threonine 509 (Altiok et al., 1999; Cortez et al., 1999; O'Brien et al., 1999; Ruffner et al., 1999; Gatei et al., 2000 Gatei et al., , 2001 Lee et al., 2000; Tibbetts et al., 2000) . All these phosphorylation sites (serines 988, 1387, 1423, 1457, 1497, 1524 and 1572 , and threonine 509) are conserved in the bovine sequence. We have demonstrated that bovine BRCA1 is phosphorylated, but we have not confirmed phosphorylation at specific sites in bovine BRCA1. Importantly, phosphorylation following genotoxic stress with adriamycin was blocked by the ATM/ATR inhibitor wortmannin in preliminary experiments.
The crystal structure of the paired human BRCT domains provides evidence that two hydrophobic residues at the end of the second BRCT domain (L 1854 I 1855 ) are critical because they are packed in the hydrophobic core of the domain (Williams et al., 2001) . A truncation that eliminates these amino acids (BRCA1 1853term ) is associated with human breast cancer (11). The 1853term truncation results in loss of these critical hydrophobic amino acids and thus destabilizes the tertiary structure of this region (Williams et al., 2001) . The bovine BRCA1 sequence provides evolutionary evidence regarding these hydrophobic residues, and the importance of residues distal to the C-terminal end of the second BRCT domain. The second BRCT domain of bovine BRCA1 terminates with four amino acids that are homologous to the human (YLVP in bovine and YLIP in human BRCA1). Termination of the bovine protein directly after the critical hydrophobic pair (LV) provides evidence that amino acids distal to the BRCTs are dispensable, and generally supports the model that protein destabilization accounts for the disease phenotype of mutations like 1853term that truncate the protein upstream of Leu 1854 in the human sequence.
While the predicted sequences of bovine and human CTDs (exons 14-24) are highly conserved, we noticed that the bovine CTD was much less acidic (overall charge ¼ À15) compared to the human CTD (overall charge ¼ À29). Since spurious transcriptional activation activity has been repeatedly linked to acidic domains (Ma and Ptashne, 1987; Benuck et al., 1999) , we wondered whether the bovine gene would interact with RNA polymerase II. We found that both human and bovine CTDs bound RNA polymerase II but that they had markedly different activities when tested in a mammalian GAL4 transcriptional activation assay. The less-charged bovine CTD had dramatically reduced activity when compared to the human sequence (4-5-fold in bovine compared with 21-29-fold in human). We went on to test more complete fusions, including fulllength human and bovine BRCA1 proteins in the mammalian GAL4 transactivation assay, and were surprised to find that even the human protein had no activity when tested as a full-length protein. The fact that full-length proteins (human or bovine) interact with RNA polymerase, but are inactive in the GAL4 assay, indicates that BRCA1 may not recruit RNA polymerase II to DNA as would be expected of a traditional transcriptional activator. It seems more plausible that transcriptional activation is not a significant contributor to function of BRCA1. Preliminary experiments with the CTD from mouse BRCA1, and the full-length murine protein, also show extremely low activity in this assay (Krum et al., in preparation) . This appears to be the first report that includes full-length BRCA1 proteins (human and bovine) in the mammalian GAL4 transcriptional activation assay.
The lack of transcriptional activation by the bovine BRCA1 CTD suggested that bovine BRCA1 does not function as a direct transcriptional activator. Given an extensive literature describing an ability of the human CTD to activate GAL4-dependent promoters (Chapman and Verma, 1996; Monteiro et al., 1996; Hu et al., 2000) , this result was unexpected. In our studies, GAL4-fusions with the full-length human or bovine cDNAs never activated transcription to a greater extent than did fusions of the human CTD from the well-studied 1853term human disease allele, indicating that fulllength BRCA1 gene products would be classified as null alleles in these assays. Since both human and bovine BRCA1 show interaction with RNA polymerase II, we hypothesize that BRCA1 could associate with the large RNA polymerase II complex that regulates transcription, transcription-coupled repair or chromatin remodeling, but is unlikely to act as a canonical transcriptional activator, that is, a protein containing an AD and a DBD that recruits and/or correctly orients RNA polymerase II at sequence-specific promoters (Featherstone, 2002) .
In conclusion, we have characterized a bovine ortholog of BRCA1, which has a uniquely truncated C-terminus but otherwise appears more similar to the human protein than any other full-length BRCA1 ortholog that has been functionally characterized. The reduced size of the C-terminal tail in bovine BRCA1 provides a genetic reference for analysis of critical amino acids in the C-termini of BRCA1 genes. Apart from the tail, bovine BRCA1 is homologous to the human protein and may provide a valuable reference for validating the significance of specific human BRCA1 sequence variants. Finally, the present study calls into question the hypothesis that BRCA1 acts as a direct transcriptional activator. Transcriptional activation was only significant in the human CTD, which is more acidic than the similar region of the murine, dog, chicken or bovine sequences. In support of this interpretation, direct transcriptional activation activity was absent from both human and bovine full-length proteins when tested in the GAL4 assay. The failure of BRCA1 to act as a direct activator of transcription should not be confused with an ability to regulate transcription through other means, including interaction with the RNA polymerase II holoenzyme. The specific role of BRCA1 in regulating RNA polymerase II function, therefore, remains to be described.
Materials and methods
Tissue and RNA
Total RNA was isolated from bovine spleen and testes (PelFreez, Rogers, AR, USA) with Trizol Reagent (Life Technologies, Rockville, MD, USA). Reverse transcription reactions contained 1.4 mg total RNA, 1 Â AMV reaction buffer, 5 mm MgCl 2 , 1mm dNTPs, 50 U RNase inhibitor, 20 U AMV reverse transcriptase (Roche, Indianapolis, IN, USA), and were incubated for 15 min at 251C, followed by 1 h at 421C. Reactions were primed with 1.6 mg oligo dT primer or with the internal primer 5 0 -ACCCCCCATCGCACGAGTCATCA-GAAG-3 0 .
PCR
All PCR reactions were carried out with the following conditions: 0.5 ml first-strand cDNA, 1 Â Dynazyme EXT buffer, 0.5 U Dynazyme EXT (Finnzymes), 250 mm dNTPs and 1 mm each oligo. PCR conditions were as follows: one cycle of 951C for 5 min; 35 cycles of 941C for 20 s, 501C for 20 s, 721C for 2 min; and one cycle of 721C for 5 min.
Cloning of bovine BRCA1
The sequences of BRCA1 mRNAs were deduced from several cloned segments isolated from three independent RT-PCR reactions from bovine RNA. The N-terminus was cloned using a forward primer to the first 14 nucleotides of the open reading frame, all 14 of which are 100% identical in human, murine, rat and canine BRCA1 (5 0 -ATGGATTTATCTGC-3 0 ). The reverse primer was designed based on a partial sequence from exon 11 (accession number AJ403968 (Madsen et al., 2001 )) (5 0 -TGCCTATCCTTACATGTGCCCTTAC-3 0 ). The 995 base pair PCR product was ligated into pCR-blunt II TOPO (Invitrogen, Carlsbad, CA, USA). Exon 11 was cloned by RT-PCR, also using primers derived from the partial exon 11 sequence (Madsen et al., 2001) . The 3108 base pair PCR product was ligated into pcDNA3.1D/V5-His-TOPO (Invitrogen). Exons 12-24 were cloned by RT-PCR using a forward degenerate primer in the 3 0 region of exon 11, in a region highly conserved across many species (5 0 -GTTTGYYCTGA-GACACCKGATGACCT-3 0 ). The reverse primer was designed based on an EST (accession number AF284013) of about 600 nucleotides (5 0 -GACAGGCCCTATCTCTAATA-TACAC-3 0 ). The 2192 base pair PCR product was ligated into pCR-blunt II TOPO (Invitrogen) to create pCR-bovineBR-CA1-CTD (CTD of bovine BRCA1, amino acids 1364-1849).
To make a full-length cDNA, the N-terminus was digested with EcoRI and ligated to exon 11 in pcDNA3.1D/V5-His-TOPO, also digested with EcoRI. The C-terminus was digested with BamHI and XhoI, and ligated into exons 1-11 in pcDNA3.1D/V5-His-TOPO. The sequences of two exon 11 splice variants were deduced from RT-PCR products obtained from spleen RNA using the following oligonucleotides: 5 0 -GAGTGAACCTGAAAATCCTACCTTG-3 0 and 5 0 -AGC-TAACTACCCATTTTCCTCCTG-3 0 .
Plasmids
The human BRCA1-CTD (CTD of human BRCA1, amino acids 1380-1863) was generated by PCR using full-length human BRCA1 cDNA as the template (a gift from Dr E Solomon, Guy's Hospital, London, UK) using the primers 5 0 -CCAAGAATTCCTGAAGACTGCTCAGGGCTATCC-3 0 and 5 0 -CTCATTCTTGGGGTCCTGTGG-3 0 . The canine BRC A1-CTD (amino acids 1380-1879) was generated by PCR with the following primers: 5 0 -AAACGAGCCTCTCTGAA-GACTGTTCC-3 0 and 5 0 -GGATCCTTACACGCATG-GCT GGCTGG-3 0 (accession number U50709). All BRCA1 CTDs were ligated into pCR-blunt II TOPO (Invitrogen). The pCR-BRCA1-CTD inserts were released with EcoRI and BamHI, and religated into the GAL4 vector pFA-CMV (Stratagene, La Jolla, CA, USA). The full-length bovine BRCA1 GAL4 fusion was created by digesting pcDNA3.1D/V5-His-TOPO-bovineBRCA1 with NotI and XhoI, using Klenow polymerase to make blunt ends, and ligating it to pFA-CMV digested with SmaI. The human BRCA1-GAL4 vector was a kind gift from Alvaro Monteiro, Rockefeller University. To create the GST fusions with the bovine BRCA1-CTD domain, the pCRbovineBRCA1-CTD vector was digested with EcoRI, and the BRCT domain-containing fragment was ligated into pGEX-2TK (Amersham Pharmacia Biotech, Piscataway, NJ, USA) also digested with EcoRI. 
Alignments and deduced protein structure
Chromosomal mapping
Primers were designed to amplify fragments from the exon 11 regions of bovine BRCA1 but not from DNA isolated from hamster cells. Two successful primer pairs were identified (5 0 -GGAAGGACGCTCAAAACATC-3 0 and 5 0 -GGCCCTTT-CACCCATACAC-3 0 , which generated a 223 base pair fragment, and 5 0 -CACTCTTCAATGATTCTAGGTTCTC-3 0 and 5 0 -CTGTTGCCACTGAGGGTCTG-3 0 , which generated a 233 base pair fragment). These primers were used to screen a 31-clone bovine-hamster somatic cell hybrid panel (98SCP31) described in Adkison et al. (1988) and Barendse et al. (1991) . Initial mapping to BTA 19 was confirmed and extended by analysis of a 5000 rad radiation hybrid panel (RHBov5RAD) as previously described (Band et al., 2000) . The logarithm of the odds (LOD score) and recombination fraction (y) were calculated for BRCA1 and 55 markers previously mapped to BTA19 using the RHMAPPER program (Cox and Burmeister, 1990 ; http://www-genome.wi.mit.edu/ftp/pub/software/ rhmapper/doc/rhmapper.html).
Antisera production
Recombinant bBRCA1-CTD was generated by transforming pGEX-2TK-bovineBRCA1-CTD into BL-21-Codon-Plus-RIL bacterial cells (Stratagene) and inducing with 0.2 mm IPTG. Glutathione-conjugated agarose beads were added to total bacteria lysate. The beads were washed three times with phosphate-buffered saline, followed by an elution step with excess glutathione. Aliquots of purified fusion proteins were analysed by SDS-PAGE, followed by visualization of proteins with Coomassie blue. A total of 10 mg of GST-bovineBRCA1-CTD (495% pure) was diluted with Freund's adjuvant and injected into the peritoneal cavity of Balb/c mice, and the procedure was repeated with booster injections using incomplete adjuvant at 15-day intervals. Finally, 10 mg of GSTbovineBRCA1-CTD diluted with normal saline was injected into the tail vein three days before exsanguination.
Immunoblotting, immunoprecipitation and immunofluorescence
293T cells were transfected by calcium phosphate precipitation with 3 mg pFA-GAL4 plasmids, and total cellular protein was lysed in SDS-loading buffer containing 10 mm DTT. HBL100 cells (ATCC, Manassas, VA, USA), MDBK (ATCC) and bovine testes (Pel-Freez) were lysed in EBC (50 mm Tris pH 8, 120 mm NaCl, 0.5% NP-40) containing 100 mm Na 3 VO 4 and 10 mm NaF and a protease inhibitor cocktail (Complete TM without EDTA, Roche). All lysates were clarified by centrifugation (14 000 rpm, 10 min, 41C) and total protein was immunoprecipitated overnight with 1 ml of serum generated against bovine BRCA1-CTD. Cell lysates or immunoprecipitates were run on either 5 or 10% SDS-PAGE gels. Proteins were then transferred to PVDF membranes, blocked in 5% nonfat dry milk and incubated with a primary antibody generated against the GAL4 DBD (Upstate Biotechnology, Charlottesville, VA, USA), RNA polymerase II (clone 8WG16, QED Biosciences, San Diego, CA, USA, a kind gift from Dr Michael Carey (UCLA, Los Angeles, CA, USA)), or one of the mouse antibodies generated against bovine BRCA1-CTD (see above). Blots were then washed and exposed to a goat anti-rabbit or goat anti-mouse horseradish peroxidase conjugated secondary antibody (Pierce, Rockford, IL, USA).
Blots were developed with a chemiluminescence detection substrate (SuperSignal TM , Pierce) and exposed to film. Parallel blots were reprobed with rabbit antisera for b-catenin (SigmaAldrich, St Louis, MO) to assess the equivalence of protein levels in the various extracts.
For immunofluorescence, BAECs (a gift of Dr Luisa IruelaArispe, University of California, Los Angeles), grown in DMEM with 10% fetal calf serum and penicillin/streptomycin, were plated in eight-well chamber slides (Nalge Nunc, Rochester, NY, USA), and were either left untreated, or were treated with 1 mm HU or 5 mg/ml aphidicolin for 24 h. The cells were probed with a primary antibody generated against bovine BRCA1-CTD (C3F, 1 : 5000) and a highly crossabsorbed Alexa488-conjugated goat anti-mouse secondary antibody (Molecular Probes Inc., Eugene, OR, USA). A Leica DM IRBE fluorescent microscope equipped with a 63 Â objective (Leica Microsystems, Germany) and Openlab software (Improvision, Lexington, MA, USA) were used for image acquisition. Cell cycle analysis was performed on similarly stained cells using a Laser Scanning Cytometer (LSC TM ; Compucyte, Boston, MA, USA). Cells were counterstained with propidium iodide (5 mg/ml) to identify DNA and to distinguish cell cycle stage.
Luciferase assays
In all, 50 000 MCF7, T47D or 293T cells were plated in 24-well tissue culture dishes and transfected with 100 ng of the pFA-GAL4-BRCA1 fusion vectors or the GAL4 vector (pFA-CMV) alone, along with 1 mg of the reporter vector pFR-luc (Stratagene), and 100 ng of pRL-SV40 (Promega, Madison, WI, USA) as a transfection control. Each transfection was done in triplicate and the entire assay was repeated at least five times for each construct. At 24 h after transfection, cells were lysed in 100 ml of lysis buffer and luciferase assays were performed according to the manufacturer's protocol (Promega, Dual-Reporter TM Assay Kit). To obtain 'fold induction,' all values were normalized as follows: the raw firefly luciferase value (pFR-luc) was divided by the internal Renilla Luciferase value (pRL-SV40). Subsequently, all results were divided by the value (averaged over triplicate samples) obtained for the pFA-CMV vector control, which expressed the GAL4 DBD alone.
GST pull-down assay
A total of 5 mg of GST fusion protein bound to glutathioneagarose beads was incubated overnight at 41C with HBL100 cells or MDBK cells lysed in EBC buffer with protease inhibitor cocktail (Complete TM without EDTA, Roche). After three washes in lysis buffer, the beads were treated with CIP (New England Biolabs) and eluted with SDS-PAGE loading buffer. Eluted proteins were subjected to SDS-PAGE and immunoblotting with antisera to the 220 kDa subunit of RNA Polymerase II (QED Biosciences). The same membrane was then probed with a GST-Horseradish peroxidase antibody (Roche) and bound complexes were visualized with a chemiluminescence detection substrate (Pierce).
Nucleotide sequences
The nucleotide sequence data reported in this paper have been submitted to GenBank. The cDNA sequence for full-length bBRCA1 has been assigned the accession number AY077732, and the splice variants D11 and D11b are assigned AF479648 and AF479649, respectively.
